Clinical Efficacy of Sacubitril Valsartan Combined with Metoprolol in Chronic Heart Failure
Objective:To investigate the effect of Sacubitril Valsartan combined with Metoprolol in patients with chronic heart failure(CHF).Method:A total of 60 patients with CHF admitted to Shiqian County People's Hospital from June 2022 to June 2023 were selected as the study objects and divided into two groups according to random number table method,with 30 cases in each group.The control group was treated with Metoprolol,and the observation group was treated with Sacubitril Valsartan on the basis of control group.The clinical efficacy,vascular endothelial function,cardiac function index,serological index and incidence of adverse reactions were compared between the two groups.Result:The effective rate of observation group was 93.33%,which was higher than 73.33%of control group,and the difference was statistically significant(P<0.05).After treatment,left ventricular ejection fraction(LVEF),stroke volume(SV),and nitric oxide(NO)in observation group were higher than those in control group,left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD),endothelin-1(ET-1),N-terminal pro-brain natriuretic peptide(NT-proBNP),hypersensitive C-reactive protein(hs-CRP),angiotensin Ⅱ(AngⅡ)levels,and creatine kinase(CK)were lower than those of control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Sacubitril Valsartan combined with Metoprolol can enhance the treatment effect of CHF,accelerate the improvement of heart function and the relief of heart failure symptoms,with high safety.
Chronic heart failureSacubitril ValsartanMetoprololClinical efficacyVascular endothelial function
万方数据
维普
